This raises the possibility that improvement in insulin sensitivity seen with vildagliptin in those with relatively well-controlled diabetes may be a drug-specific effect, rather than a class effect of DPP 4 inhibitors [22]. This evidence concerns the gene INS and diabetes mellitus.